Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578268 | 0.76 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1TSHRMAPK1USP2 | |
| SCHEMBL2448262 | 0.76 | ALDH1A1 (0.35) | SMN1; SMN2ALDH1A1TSHRMAPK1USP2 | |
| SCHEMBL1035871 | 0.75 | CYP2B6 (0.35) | — | |
| SCHEMBL23075936 | 0.74 | ALDH1A1 (0.34) | SMN1; SMN2ALDH1A1TSHRMAPK1USP2 | |
| SCHEMBL26381544 | 0.74 | ALDH1A1 (0.34) | SMN1; SMN2ALDH1A1TSHRMAPK1USP2 | |
| SCHEMBL946474 | 0.74 | TSHR (0.35) | SMN1; SMN2ALDH1A1TSHRMAPK1USP2 | |
| SCHEMBL4471161 | 0.71 | SMN1; SMN2 (0.37) | SMN1; SMN2ALDH1A1TSHRMAPK1USP2 | |
| SCHEMBL85406 | 0.71 | SMN1; SMN2 (0.37) | SMN1; SMN2ALDH1A1TSHRMAPK1USP2 | |
| SCHEMBL2441206 | 0.70 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1TSHRMAPK1USP2 | |
| SCHEMBL23075441 | 0.70 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1TSHRMAPK1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2277884-B1 | ANTHRACYCLINE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PREPARATION METHODS AND USES THEREOF | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2017-08-23 | — | — | EP | disclosed |
| US-9115165-B2 | Tetracyclic anthraquinone antibiotic derivatives with high activity, process for preparing the same and use thereof | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2015-08-25 | — | — | US | disclosed |
| US-20110224161-A1 | TETRACYCLIC ANTHRAQUINONE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2011-09-15 | — | — | US | disclosed |
| EP-2277884-A1 | ANTHRACYCLINE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PREPARATION METHODS AND USES THEREOF | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2011-01-26 | — | — | EP | disclosed |
| WO-2006038001-A1 | AMINOPYRIMIDINE DERIVATIVES AS JNK INHIBITORS | CELLTECH R & D LIMITED (GB) | 2006-04-13 | — | — | WO | disclosed |
| EP-0088050-A2 | Coloured photo-hardenable composition | CIBA-GEIGY AG (CH) | 1983-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224161-A1 | TETRACYCLIC ANTHRAQUINONE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PROCESS FOR PREPARING THE SAME AND USE THEREOF | DHPS, TBCA, ANTXR2 | SMN1; SMN2 4513/4885ALDH1A1 909/4885TSHR 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.